Search Results
Your search for ,now matches 6674 pages
Showing 1801 - 1850First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
ASCO Issues Guideline on Dyspnea in Advanced Cancer
ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.1 Dyspnea—or breathlessness—is a common and distressing symptom affecting upward of 70% of patients with advanced cancer.2 “Dyspnea is a highly prevalent symptom, particularly when people...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Drive, Curiosity, and a Love of Science: One Nurse’s Road to a Leadership Role in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Deborah Watkins Bruner, RN, PhD, FAAN, noted for her work in patient-reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
AACR to Recognize the St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team With 2021 Team Science Award
The American Association for Cancer Research (AACR) will recognize the St. Baldrick’s Foundation–Stand Up To Cancer (SU2C) Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. In early 2013, the St. Baldrick’s Foundation and SU2C collaborated to create a Pediatric Cancer Dream Team...
Expert Point of View: Ezra E.W. Cohen, MD
Formal discussant of the -LIBRETTO-001 trial, Ezra E.W. Cohen, MD, Associate Director for Translational Science and Leader of the Solid Tumor Therapeutics Research Program at the Moores Cancer Center at UC San Diego Health, was encouraged by this trial and said that detection of genetic...
Selpercatinib Makes Inroads in Other RET Fusion–Positive Tumor Types
The selective RET inhibitor selpercatinib is now approved for RET fusion–positive lung and thyroid cancers. New evidence presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting 2021 shows that selpercatinib is active against other RET fusion–positive...
ASCO’s President-Elect Focuses on Advancing Equitable Cancer Care Through Innovation
Internationally renowned for his pioneering research in combining high-dose radiation therapy and chemotherapy in the treatment of locally advanced head and neck cancer to improve patient survival, ASCO’s President-Elect Everett E. Vokes, MD, FASCO, is dedicating his tenure as President to...
First-Line Nivolumab/Relatlimab vs Nivolumab Alone for Advanced Melanoma
Treatment with the anti–PD-1 therapy nivolumab plus the LAG-3–blocking antibody relatlimab extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma. Findings from the RELATIVITY-047 trial were presented by Evan J. Lipson, MD, and colleagues...
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Prompted by a rise in cases of colorectal cancer in people younger than 50, the U.S. Preventive Services Task Force (USPSTF) has recommended that individuals at average risk for the disease begin screening exams at age 45 instead of the traditional age of 50. The guideline changes, published in...
TLR4 as a Possible Therapeutic Target to Mitigate Cisplatin-Induced Hearing Loss
A research team has identified a receptor in cells that could play a role in preventing permanent hearing loss in childhood cancer survivors treated with the drug cisplatin. The researchers believe that by inhibiting the receptor, they may be able to better control otoxicity, according to findings...
Effect of Publication of the LACC Trial on Use of Minimally Invasive Surgery for Cervical Cancer
The Laparoscopic Approach to Cervical Cancer (LACC) trial, reported in November 2018, showed poorer disease-free and overall survival with minimally invasive vs open radical hysterectomy for early-stage cervical cancer. In a study recently reported in a letter in The New England Journal of...
Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease-free survival in the node-positive or intent-to-treat population, as reported by Harbeck et al at the 2020 ASCO Virtual...
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics
The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors. This research was presented by...
Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated
PRESERVE 4 (ClinicalTrials.gov identifier: NCT04863248)—a multicenter, randomized, double-blind, placebo-controlled phase II study of trilaciclib administered prior to docetaxel in patients with metastatic non–small cell lung cancer (NSCLC) in the second- and third-line setting who have previously...
How MRD Assessment May Help Guide Treatment Selection for Patients With AML
Complete morphologic remission is considered the first requirement for achieving long-term, leukemia-free survival and a potential cure in patients with acute leukemia, including acute myeloid leukemia (AML), and is the goal of all therapeutic strategies to date. Recognizing that the majority of...
ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations
ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations. Guideline Co-Chair Nasser H. Hanna, MD, of the Indiana University Simon...
Fostering a Global Community of Early-Career Oncologists, Virtually
In a typical year, the new participants in ASCO and Conquer Cancer’s International Development and Education Awards (IDEA) and International Development and Education Awards–Palliative Care (IDEA-PC) program would arrive at the McCormick Place Convention Center just ahead of the ASCO Annual...
What You Need to Know About Cancer and the Coronavirus
As a three-time breast cancer survivor, when the COVID-19 pandemic hit the United States this past January, I knew I had to do everything I could to avoid getting the virus. A host of lingering side effects from my surgeries, chemotherapy, and radiation treatments have left me with cardiovascular...
Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer
It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a...
COVID-19 Pandemic Underscores Shortage of Oncologists
The expected surge of patients, some with advanced cancers, wanting and needing oncology care as the COVID-19 pandemic ebbs, underscores the need for more oncologists, according to Barbara L. McAneny, MD, MACP, FASCO, cofounder and Chief Executive Officer, New Mexico Oncology Hematology...
Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic
Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...
Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology
Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...
AACR Inaugurates New Leadership at Virtual AACR Annual Business Meeting 2021
The American Association for Cancer Research (AACR) welcomed David A. Tuveson, MD, PhD, FAACR, as President of the organization for 2021–2022. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 12. Dr. Tuveson is Director of the Cold Spring Harbor Laboratory Cancer...
Cannabis
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this article, Nirupa Raghunathan, MD, and Jyothirmai Gubili, MS, focus on the increasing use...
City of Hope Renames Research Center as the Arthur Riggs Diabetes & Metabolism Research Institute
City of Hope has announced the renaming of its diabetes research center as the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its long-time director and research pioneer. Arthur Riggs, PhD, is known for scientific achievements that include developing the technology leading...
A Sense of Duty Shapes the Career of Medical Oncologist Aparna Parikh, MD
By way of her family lineage, Aparna Parikh, MD, seemed destined for a career in medicine. “Both of my parents are physicians, as well as my maternal grandfather. I have two other siblings, all of whom are in the medical field. Medicine has always been part of my life since childhood. My parents...
‘MethylationToActivity’: A Deep Learning Framework for Epigenetic Research
Scientists at St. Jude Children’s Research Hospital are using a type of machine learning to put a new twist on an established technique. The researchers created MethylationToActivity (M2A), a framework for using DNA methylation data to reveal promoter activity and gene expression. The results were...
Expert Point of View: Ursula Matulonis, MD, and Konstantin Zakashansky, MD
Perspectives on ARIEL4 were provided for The ASCO Post by the invited discussant Ursula Matulonis, MD, Professor of Medicine, Harvard Medical School, and Chief of Gynecologic Oncology and the Brock Wilson Family Chair at Dana-Farber Cancer Institute, Boston, and by Konstantin Zakashansky, MD,...
Chênevert Family Brain Tumor Center Launched at Yale
Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...
Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race
A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...
Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?
Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This question was addressed at PER’s Miami Breast Cancer Conference, held virtually this year, by Adam M....
Accuracy of Lung Cancer Risk Model in Diverse Populations
A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...
Expanding Role of Liquid Biopsies in Cancer Detection and Therapeutics: Now and in the Near Future
“It is possible that within the next several years, perhaps 75% of cancers can be detected by screening,” Bert Vogelstein, MD, PhD, projected at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 “I anticipate that perhaps 50% of cancers can be detected...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
Risk of Colorectal Cancer and Colorectal Polyps in First-Degree Family Members
Researchers have demonstrated a possible connection between colorectal polyps in close relatives and the risk of developing colorectal cancer. The study, which was published by Song et al in the British Medical Journal, is of potential consequence for cancer screening procedures. Colorectal cancer...
Cryoablation Emerging as Effective Treatment for Low-Risk Breast Cancers
Nonsurgical breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, is proving to be an effective alternative to surgery for small breast tumors with low-risk features in women older than age 60. These were the early findings from 3-year results of the...
COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization
The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...
YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content
Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...
New Research Finds Few Young Adult Men Have Received the HPV Vaccine
Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...
Hormonal Intrauterine Device Under Study for Managing Early Endometrial Cancer
Disease regression was observed in 82% of women with endometrial hyperplasia with atypia and 43% of women with endometrial cancer after treatment for 6 months with a hormonal intrauterine device in a phase II study reported during the virtual edition of the Society of Gynecologic Oncology (SGO)...
Chernobyl at 35 Years: An Oncologist’s Perspective
Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...
Incidence and Cancer-Related Mortality in Belize
Located on the northeast coast of Central America, Belize is a small, upper middle–income country bordered by Mexico, Guatemala, and the Caribbean Sea. Belize has a population of about 405,000 people (Table 1), of which about 15% are immigrants. Belize is considered to be one of the most...
Cancer Care in Sudan During the COVID-19 Pandemic
Sudan is one of Africa’s largest countries, rich in underutilized natural resources but rife with conflicts and civil wars that have been ongoing since it gained its independence in 1956. These problems have reflected negatively on the health-care system. Khartoum, the capital of Sudan, is a busy...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
Addressing Oncologist Burnout, Emotional Well-Being, and Moral Distress in the Pandemic
JCO Oncology Practice recently published an editorial that examines the intensified burnout oncology practitioners are experiencing due the COVID-19 pandemic and outlines critical interventions to support oncologists now and throughout a long-term recovery.1 The article was written by past,...
Nivolumab/Ipilimumab Plus Two Cycles of Histology-Based Chemotherapy: Another Option in First-Line Metastatic NSCLC
Introduction of immunotherapy has revealed a paradigm shift in the management of patients with metastatic non–small cell lung cancer (NSCLC) that does not harbor a therapeutically targetable driver mutation. Over the past 5 years, several trials have informed treatment decisions, based on disease...
Expert Point of View: Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office, found the MANIFEST-2 findings to be highly noteworthy. He cited a...
MANIFEST-2: CPI-0610 Shows Benefit in Myelofibrosis
The novel targeted agent CPI-0610 enhanced responses to ruxolitinib in patients with myelofibrosis enrolled in the global phase II MANIFEST-2 trial, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 “Preliminary data demonstrate the...
